参麦注射液联合吉西他滨和顺铂对晚期NSCLC患者肿瘤标志物、T淋巴细胞亚群和血清凋亡分子的影响  

Effects of Shenmai Injection Combined with Gemcitabine and Cisplatin on Tumor Markers,T Lymphocyte Subsets and Serum Apoptotic Molecules in Patients with Advanced NSCLC

作　　者：陈慧昱 柯丽 王赟 刘鑫佳 杨光 CHEN Hui-yu;KE Li;WANG Yun;LIU Xin-jia;YANG Guang(Department of Clinical Laboratory,The First Affiliated Hospital of Air Force Military Medical University,Xi'an,Shaanxi,710032,China;Department of Oncology,The First Affiliated Hospital of Air Force Military Medical University,Xi'an,Shaanxi,710038,China)

机构地区：[1]空军军医大学第一附属医院检验科,陕西西安710032 [2]空军军医大学第二附属医院肿瘤科,陕西西安710038

出　　处：《现代生物医学进展》2024年第20期3984-3986,共3页Progress in Modern Biomedicine

基　　金：陕西省重点研发计划项目(2019SF-085)。

摘　　要：目的:探讨参麦注射液联合吉西他滨和顺铂对晚期非小细胞肺癌(NSCLC)患者肿瘤标志物、T淋巴细胞亚群和血清凋亡分子的影响。方法:将在2020年3月~2022年12月期间我院收治的118例晚期NSCLC患者以随机数字表法分为联合组(n=59,参麦注射液联合吉西他滨和顺铂治疗)和对照组(n=59,吉西他滨和顺铂治疗)。对比两组肿瘤标志物水平、T淋巴细胞亚群、凋亡分子。结果:与对照组相比,联合组治疗后细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、鳞状细胞癌相关抗原(SCC)、糖类抗原125(CA125)、B淋巴细胞瘤(Bcl-2)、生存素(Survivin)、CD8^(+)更低,Bcl-2相关X蛋白(Bax)、CD3+~、CD4^(+)、CD4^(+)/CD8^(+)更高(P<0.05)。结论:参麦注射液联合吉西他滨和顺铂治疗晚期NSCLC患者,能够降低肿瘤标志物水平,减轻患者免疫抑制,调节血清凋亡分子水平。Objective:To investigate the effects of shenmai injection combined with gemcitabine and cisplatin on tumor markers,T lymphocyte subsets and serum apoptotic molecules in patients with advanced non-small cell lung cancer(NSCLC).Methods:118patients with advanced NSCLC who were admitted to our hospital from March 2020 to December 2022 were divided into combined group(n=59,treated with shenmai injection combined with gemcitabine and cisplatin)and control group(n=59,treated with gemcitabine and cisplatin)by random number table method.The tumor marker level,T lymphocyte subsets and apoptotic molecules were compared between two groups.Results:Compared with control group,cytokeratin 19 fragment(CYFRA21-1),carcinoembryonic antigen(CEA),sqamous cell carcinoma antigen(SCC),carbohydrate antigen 125(CA125),B-cell lymphoma(Bcl-2),Survivin(Survivin),CD8^(+)were lower in combined group after treatment,and Bcl-2-related X protein(Bax)and CD3^(+),CD4^(+),CD4^(+)/CD8^(+)were higher(P<0.05).Conclusion:Shenmai injection combined with gemcitabine and cisplatin for the treatment of advanced NSCLC Patients,which can reduce tumor markers level,reduce the immunosuppression of patients,regulate serum apoptotic molecules level.

关 键 词：参麦注射液 吉西他滨 顺铂 晚期非小细胞肺癌 肿瘤标志物 T淋巴细胞亚群 凋亡分子 

分 类 号：R734.2[医药卫生—肿瘤]